论文部分内容阅读
目的:探讨影响急性髓系白血病(AML)伴Inv(16)/t(16;16)患者临床特征、细胞遗传学特点以及生存、预后的主要因素。方法:对43例AML伴Inv(16)/t(16;16)患者进行总结分析、随访,了解一般情况、免疫分型、染色体核型及治疗、生存情况,对影响总体生存时间、无复发生存时间的因素进行统计学分析。结果:43例AML伴Inv(16)/t(16;16)患者总完全缓解(CR)率97.5%,1疗程CR率92.6%。所有患者的中位总生存时间(OS)未达(0.33～81.9个月),中位无复发生存(RFS)63.4(3.02～81.9)个月。3年OS率69%,5年OS率56%;3年RFS率68%,5年RFS率43%。统计学分析可见:≥45岁的患者与<45岁患者相比较OS、RFS期短,预后差。发病时一般特征、染色体核型及巩固治疗过程中采用中剂量Ara-C治疗的疗程数与OS无关。结论:年龄≥45岁是AML伴Inv(16)/t(16;16)的主要预后不良因素。
Objective: To investigate the clinical characteristics, cytogenetic characteristics and survival and prognosis of patients with acute myeloid leukemia (AML) associated with Inv (16) / t (16; 16). Methods: A total of 43 patients with AML with Inv (16) / t (16; 16) were analyzed retrospectively. The general situation, immunophenotype, chromosome karyotype, treatment and survival were investigated. Survival time of the factors for statistical analysis. Results: The total complete remission (CR) rate was 97.5% in 43 cases of AML with Inv (16) / t (16; 16), and the CR rate of one course of treatment was 92.6%. All patients had a median overall survival (OS) of less than 0.33 to 81.9 months and a median recurrence-free survival of 63.4 (3.02 to 81.9) months. The 3-year OS rate was 69% and the 5-year OS rate was 56%. The 3-year RFS rate was 68% and the 5-year RFS rate was 43%. Statistical analysis shows that: ≥45 years of age patients with OS compared to <45 years, RFS period is short, the prognosis is poor. The general characteristics of onset, chromosome karyotypes and the number of courses of treatment with mid-dose Ara-C during consolidation therapy were independent of OS. CONCLUSIONS: Age ≥ 45 years old is a major adverse prognostic factor for AML with Inv (16) / t (16; 16).